1Department of Radiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences Yazd, Iran
2Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran
3Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4Psychiatric Department and Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
5Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
Introduction: Differentiated thyroid carcinoma (DTC) is associated with excellent prognosis and high survival rates. This study was conducted to evaluate the influence of baseline and treatment-related factors on the health related quality of life (QoL) in cured DTC. Methods:This study was an analytic cross-sectional study on radio-iodine (RAI) treated DTC patients during 2011-2012. The data on patients’ QoL were recorded using a validated EORTC QLQ-C30 version 3.0. Also a checklist was used to record demographic data as well as information about the educational, marital and economic status. Duration of follow up, frequency of RAI therapies and number of surgeries were also recorded. General linear model multivariate analysis of variances (GLM-MANOVA) was used to analyze the data. Results:Totally 435 DTC patients, 41.11±11.25 years, 77% female were assessed. Most of them were married (79%) and unemployed (57%). Global health and Qol as well as functional domains were better in women, single and higher educated patients. The QoL score in female cases was better in four functional subdomains, i.e physical, emotional, role and cognitive, but not for social functioning. QoL was adversely affected by increased number of radio-iodine therapies, radio-iodine cumulative doses and number of surgeries. Conclusion: We found that quality-of-life scores are affected by the majority of socio-economic, treatment and follow-up variables. Attention to the quality of life and well-being of the patient as well as availability of professional support may be important aspects of the DTC patients’ treatment and follow-up.
Pelttari H, Sintonen H, Schalin-Jäntti C, Välimäki MJ. Health-related quality of life in long-term follow-up of patients with cured TNM Stage I or II differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2009 Mar;70(3):493-7.
Giusti M, Melle G, Fenocchio M, Mortara L, Cecoli F, Caorsi V, Ferone D, Minuto F, Rasore E. Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma. J Zhejiang Univ Sci B. 2011 Mar;12(3):163-73.
Wan Leung S, Lee TF, Chien CY, Chao PJ, Tsai WL, Fang FM. Health-related quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&N35 questionnaires. BMC Cancer. 2011 Apr 12;11:128.
Zebrack BJ, Yi J, Petersen L, Ganz PA. The impact of cancer and quality of life for long-term survivors. Psychooncology. 2008 Sep;17(9):891-900.
Husson O, Haak HR, Oranje WA, Mols F, Reemst PH, van de Poll-Franse LV. Health-related quality of life among thyroid cancer survivors: a systematic review. Clin Endocrinol (Oxf). 2011 Oct;75(4):544-54.
Malterling RR, Andersson RE, Falkmer S, Falkmer U, Niléhn E, Järhult J. Differentiated thyroid cancer in a Swedish county--long-term results and quality of life. Acta Oncol. 2010 May;49(4):454-9.
Lee JI, Kim SH, Tan AH, Kim HK, Jang HW, Hur KY, Kim JH, Kim KW, Chung JH, Kim SW. Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in Korea. Health Qual Life Outcomes. 2010 Sep 15;8:101.
Hoftijzer HC, Heemstra KA, Corssmit EP, van der Klaauw AA, Romijn JA, Smit JW. Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2008 Jan;93(1):200-3.
Taïeb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf). 2009 Jul;71(1):115-23.
Tan LG, Nan L, Thumboo J, Sundram F, Tan LK. Health-related quality of life in thyroid cancer survivors. Laryngoscope. 2007 Mar;117(3):507-10.
Safaee A, Moghim Dehkordi B. Validation study of a quality of life (QOL) questionnaire for use in Iran. Asian Pac J Cancer Prev. 2007 Oct-Dec;8(4):543-6.
Tagay S, Herpertz S, Langkafel M, Erim Y, Freudenberg L, Schöpper N, Bockisch A, Senf W, Görges R. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol. 2005 Dec;153(6):755-63.